Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Membranous nephropathy.

Claudio Ponticelli1

  • 1IRCCS Istituto Auxologico Italiano, Milan - Italy. claudio.ponticelli@fastwebnet.it

Journal of Nephrology
|June 9, 2007
PubMed
Summary
This summary is machine-generated.

Membranous nephropathy (MN) involves immune complexes damaging kidney podocytes, causing proteinuria. Treatment strategies vary, with combined therapies showing promise but requiring further research for optimal outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic kidney disease trajectories in lupus nephritis: Is progression unavoidable?

Journal of autoimmunity·2026
Same author

CRITICAL ROLE OF DYSREGULATED AUTOPHAGY IN PATHOPHYSIOLOGY OF PODOCYTOPATHY.

Kidney360·2026
Same author

Past, present and future of lupus nephritis.

Expert review of clinical immunology·2026
Same author

Kidney transplantation beyond immunosuppression: shifting the focus from graft survival to patient health.

Frontiers in immunology·2026
Same author

Predictors of Long-term Response in Patients With Lupus Nephritis.

Kidney international reports·2026
Same author

Autophagy in the Pathogenesis of Membranous Nephropathy.

Kidney medicine·2025
Same journal

Correction to: Abdominal arterial calcification profile in kidney transplant candidates: a comparison between patients with autosomal dominant polycystic kidney disease and those with other causes of kidney failure.

Journal of nephrology·2026
Same journal

Lessons for the Clinical Nephrologist. Not to see the forest for the trees: the diagnostic challenge with valproic acid-induced Fanconi-like proximal tubulopathy.

Journal of nephrology·2026
Same journal

Longitudinal trajectories in multidomain frailty among patients with chronic kidney disease.

Journal of nephrology·2026
Same journal

Correction to: Association between primary care physician-nephrologist collaboration and clinical outcomes in patients with stage 5 chronic kidney disease: a JOINT-KD cohort study.

Journal of nephrology·2026
Same journal

Improving eGFR estimation in diabetic populations: insights from real-world data.

Journal of nephrology·2026
Same journal

Barriers delaying treatment in cases at risk of crush syndrome in major disasters: Kahramanmaraş earthquake experience.

Journal of nephrology·2026
See all related articles

Area of Science:

  • Nephrology
  • Immunology
  • Glomerular Diseases

Background:

  • Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
  • Etiology is often idiopathic, but secondary causes include infections, autoimmune diseases, drugs, and toxins.
  • Pathophysiology involves immune complex deposition in the glomerular basement membrane, complement activation (C5b-9), and podocyte injury.

Purpose of the Study:

  • To review the current understanding of membranous nephropathy (MN) pathophysiology.
  • To discuss prognostic factors and treatment controversies in MN.
  • To highlight areas for future research in MN management.

Main Methods:

  • Literature review of membranous nephropathy (MN) studies.
  • Analysis of prognostic indicators including proteinuria, renal function, and biopsy findings.

Related Experiment Videos

  • Evaluation of current and potential therapeutic interventions.

    • Main Results:

    • Prognosis is poorer with severe proteinuria, advanced tubulointerstitial changes, and elevated serum creatinine.
    • Favorable prognosis is associated with complete or partial remission of proteinuria.
    • Corticosteroids alone lack strong evidence; cyclophosphamide and chlorambucil may improve remission but have adverse effects. Alternating corticosteroids and cytotoxic agents show good results.

    Conclusions:

    • Understanding MN antigens and immune pathways is crucial for targeted therapies.
    • Future research should focus on specific antibodies, glomerular permeability regulators, and complement system modulation.
    • Developing more specific and effective MN treatments is a priority.